Overall Vote Recommendation

Vote Yes; Amend

Principle Criteria

Free Enterprise

Property Rights

Personal Responsibility

Limited Government

Individual Liberty

Digest

SB 1869 revises Section 481.034 of the Texas Health and Safety Code to modify how controlled substances are scheduled within the state. It strengthens procedural safeguards for updating these schedules, particularly in response to federal regulatory changes. The bill clarifies that the Texas Commissioner of Health and Human Services is responsible for annually adopting a full, updated schedule of controlled substances. These schedules must incorporate both existing state listings and recent changes to the federal schedules unless the commissioner objects.

The bill extends the objection window for federal scheduling decisions from 30 to 90 days and requires the commissioner to publicly state the reasons for any objection. During that time, any automatic state-level change based on the federal update is paused. The bill also enhances legislative oversight by declaring that any modifications to the schedules are final and binding unless the Texas Legislature alters them through specific statutory action. It further clarifies that legislative actions impacting penalty groups do not automatically alter substance scheduling unless the law explicitly addresses the scheduling designation.

Additional requirements include mandating a public hearing in Austin for any commissioner-initiated scheduling change not based on federal action and obtaining approval from the executive commissioner. The bill reaffirms the multi-factor analysis the commissioner must consider—such as abuse potential, public health risks, and scientific evidence—before making any decision on a substance’s classification.

SB 1869 is intended to improve the consistency, transparency, and accountability of Texas’s controlled substances regulatory framework, ensuring that both public health considerations and legislative authority are respected throughout the process.

The Committee Substitute for SB 1869 introduces significant revisions to the originally filed version of the bill, primarily scaling back the broad authority it originally conferred upon the Commissioner of Health and Human Services. While both versions aim to streamline the process by which Texas aligns its controlled substance schedules with federal law, the original bill went further by centralizing decision-making power in the commissioner’s office, reducing transparency, and sharply curtailing oversight and accountability mechanisms.

Most notably, the originally filed bill included two expansive new sections—Sections 481.038 and 481.039—that granted the commissioner wide-ranging authority to interpret and enforce the statute, even overriding conflicting laws. These sections also barred judicial review of the commissioner’s decisions and penalized individuals who challenged those decisions unsuccessfully, awarding attorney's fees to the state. These provisions raised substantial concerns about due process and separation of powers, and they were fully removed in the Committee Substitute.

Additionally, the original version sought to exempt all scheduling decisions from the Texas Administrative Procedure Act (APA), meaning those actions would not be subject to public rulemaking procedures or transparency standards typically required of state agencies. This exemption, codified in a proposed amendment to Chapter 2001 of the Government Code, was also removed in the Committee Substitute, thereby reinstating procedural safeguards and public accountability.

In essence, the Committee Substitute preserves the bill’s intent to modernize controlled substance scheduling in Texas and better integrate federal changes, but it eliminates the more controversial efforts to shield those decisions from legislative, judicial, and public scrutiny. The substitute version reflects a more balanced approach—ensuring efficiency in public health administration while respecting the checks and balances foundational to Texas governance.

Author (1)

Charles Perry

Contact the Author

Sen. Charles Perry

Capitol Phone:

(512) 463-0128

Capitol Office:

EXT E1.806

E-Mail:

[email protected]

Visit Official Website

Fiscal Notes

According to the Legislative Budget Board (LBB), SB 1869 is expected to have no significant fiscal implication to the state. The agencies involved—including the Department of State Health Services (DSHS), Health and Human Services Commission (HHSC), Department of Public Safety (DPS), and the Office of Court Administration—anticipate that any additional administrative or operational duties imposed by the bill can be absorbed within existing budgets and staffing levels.

The bill’s primary fiscal effects would stem from procedural changes such as updating controlled substance schedules, conducting public hearings, and publishing scheduling decisions. However, these are either existing responsibilities or minor adjustments to current practice and thus do not trigger new resource demands of a scale that would require additional appropriations.

Similarly, no significant impact is anticipated at the local government level. County and municipal governments are not expected to bear any new enforcement, regulatory, or administrative burdens under the bill as substituted. This reinforces the conclusion that CSSB 1869 is structurally focused on administrative alignment and policy clarification rather than program expansion or financial reallocation.

In summary, the Committee Substitute’s fiscal profile is essentially neutral: it clarifies authority and procedure for managing drug schedules without introducing major new costs or liabilities for state or local governments.

Vote Recommendation Notes

SB 1869 aims to modernize how Texas updates its controlled substances schedules in response to federal changes and emerging drug threats. The bill ensures that the Department of State Health Services (DSHS), through the commissioner, will annually update the state’s drug schedules and automatically adopt changes made at the federal level unless the commissioner objects within 90 days. This responsiveness is intended to improve the state’s ability to act quickly in addressing new dangerous substances while preserving a measure of discretion to respond in ways tailored to Texas’s specific needs.

A significant improvement in the Committee Substitute is its removal of provisions from the originally filed version that would have severely limited judicial review and excluded these scheduling actions from the Texas Administrative Procedure Act. These changes were appropriately struck, restoring due process protections and reaffirming the role of the legislature and courts in maintaining accountability. This modification strengthens the bill’s alignment with constitutional principles and reflects responsiveness to concerns raised about executive overreach.

Crucially, SB 1869 does not grow government in any meaningful sense. It does not create new programs, require additional staffing, or expand agency budgets. According to the Legislative Budget Board, the bill has no significant fiscal impact, and all new responsibilities can be managed within existing agency resources. It also imposes no new burdens on local governments or Texas taxpayers. For advocates of limited government and fiscal responsibility, this is a central point in favor of supporting the bill’s advancement.

While the bill has improved substantially, it still includes certain language—such as the assertion that commissioner decisions are "final and binding unless altered by the legislature"—that could be interpreted to limit oversight or public challenge. This language, while likely intended to streamline operations, should be clarified to avoid future confusion or unintended consequences that might insulate the commissioner’s decisions from needed checks.

Therefore, Texas Policy Research recommends that lawmakers vote YES on SB 1869, but we also recommend lawmakers consider amendments to clarify interpretive language, reinforce legislative oversight, and ensure procedural transparency in future scheduling decisions.

Individual Liberty: The bill improves public health responsiveness, which can indirectly protect individual liberty by reducing the societal harm caused by dangerous, unregulated substances. However, the bill still includes language that describes the commissioner's decisions as "final and binding," which—if interpreted broadly—could restrict the ability of individuals or organizations to challenge those decisions through legal channels or public input. This language may raise concerns about due process and transparency, which are core to protecting individual liberty. However, because judicial review and APA compliance were restored in the Committee Substitute, those concerns are less severe. If amended to further clarify these areas, the bill would better uphold individual liberty.
Personal Responsibility: By ensuring that the state's controlled substance schedules are up to date and aligned with current public health realities, the bill reinforces the idea that individuals are responsible for understanding and complying with laws that regulate dangerous drugs. Clearer, more current drug scheduling makes the law easier to follow and enforce. This strengthens the principle that individuals must be held accountable for unlawful behavior, especially involving harmful or addictive substances.
Free Enterprise: The bill does not impose new licensing requirements, regulatory burdens, or taxes on businesses. It focuses solely on how substances are classified for legal and criminal purposes. That said, faster and clearer drug scheduling may benefit medical, pharmaceutical, and law enforcement sectors by reducing uncertainty about substance legality. The bill respects market freedom and does not introduce new regulatory burdens that interfere with lawful business activity.
Private Property Rights: There is no direct effect on private property ownership, land use, or property-based regulations. However, to the extent that controlled substances are considered property, updated classifications could affect whether possession is legal or subject to seizure. These implications are not new—they are inherent in the Controlled Substances Act as it exists today. No meaningful change to property rights.
Limited Government: Originally, the bill proposed significant expansions of agency power, including removing judicial review and exempting scheduling actions from the rulemaking process. The Committee Substitute corrected these issues, reintroducing appropriate checks and balances. However, the bill still centralizes decision-making authority in the commissioner’s office and includes language that could be interpreted as overly expansive if not amended. The fact that commissioner decisions are described as “final and binding” raises concerns unless clearly qualified by judicial and legislative oversight. While the Committee Substitute reflects progress, additional amendments would better secure the principle of limited, accountable government.

View Bill Text and Status